MACE risk in tofacitinib-treated patients with rheumatoid arthritis | Arthritis & Rheumatology - MD Linx

MACE risk in tofacitinib-treated patients with rheumatoid arthritis | Arthritis & Rheumatology  MD Linx

Internal Medicine Article: Risk factors for major adverse cardiovascular events in phase III and long-term extension studies of tofacitinib in patients with ...